[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Innate srl\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":103},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,45,76],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100634400","evaluation-of-the-performance-and-safety-of-a-single-dose-hyaluronic-acid-promovia-hydro-balance-in-the-treatment-of-non-traumatic-degenerative-meniscus-tears-100634400",false,"NCT07539194","Evaluation of the Performance and Safety of a Single-dose Hyaluronic Acid (Promovia Hydro Balance) in the Treatment of Non-traumatic Degenerative Meniscus Tears","Inclusion Criteria:\n\n* \\- Age between 35 and 75 years at the time of administration.\n* Presence of a symptomatic degenerative meniscus tear, not related to acute trauma, documented by MRI.\n* Positive meniscal tests.\n* Pain intensity NRS ≥ 4.\n* Willingness to participate in physical therapy or light exercise.\n* Informed consent received, understood, and signed by the patient for active participation in the study and for the processing of personal data.\n* Ability of the patient to understand the study conditions and to participate for the entire duration of the study.\n\nExclusion Criteria:\n\n* \\- Patients with traumatic meniscus tears.\n* Patients with a meniscal tear requiring surgical treatment (FLAP tear, radial tear, RAMP tear).\n* Patients with severe knee osteoarthritis.\n* Patients with axial deviation greater than 10°.\n* Patients who have undergone meniscal or ligament surgery in the previous 12 months.\n* Patients with rheumatic diseases or chondrocalcinosis.\n* Patients with signs of possible infection in the affected joint or a skin disease involving the knee (e.g., dermatitis, psoriasis).\n* Patients with diabetes.\n* Patients with coagulopathies, platelet aggregation disorders, or those receiving oral anticoagulants or antiplatelet drugs.\n* Patients receiving intra-articular corticosteroids or hyaluronic acid in the previous 12 months.\n* Pregnant or breastfeeding patients.","ALL","35 Years","75 Years",{"count":19,"type":20},25,"ESTIMATED","INTERVENTIONAL",[23],"NA","Evaluation of the performance and safety of a single-dose hyaluronic acid (Promovia hydro balance) in the treatment of non-traumatic degenerative meniscus tears",[26],"Meniscus Tears",[28,29,30,31],"meniscus tears","promovia hydro balance","hyaluronic acid","viscosupplementation","RECRUITING","2026-04-13",{"date":35,"type":36},"2026-04-20","ACTUAL",{"date":38,"type":20},"2026-04-30",{"date":40,"type":20},"2027-01-30",{"name":42,"class":43},"Innate srl","INDUSTRY",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":52,"minAge":53,"maxAge":17,"enrollmentInfo":54,"targetDuration":56,"studyType":57,"phases":4,"briefSummary":58,"conditions":59,"keywords":62,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":44},"100621182","prospective-clinical-study-using-a-medical-device-rephegyn-as-an-adjuvant-in-the-treatment-of-fungal-candidiasis-and-bacterial-infections-100621182","NCT07367295","Prospective Clinical Study, Using a Medical Device (RepHegyn) as an Adjuvant in the Treatment of Fungal (Candidiasis) and Bacterial Infections","Prospective Clinical Study, Using a Medical Device as an Adjuvant in the Treatment of Fungal (Candidiasis) and Bacterial Infections: Evaluation of the Safety and Efficacy of Rephegyn Vaginal Ovules","Inclusion Criteria:\n\n* Age between 18 and 75 years\n* Signed written informed consent.\n* At least two subjective symptoms and two objective signs (at least moderate) of vaginal inflammation due to infection. Vaginal inflammation will be assessed based on six subjective symptoms (burning, pain, itching, irritation, dyspareunia, and dysuria) and four objective signs (swelling, vaginal discharge typical of the infection, pH, and presence of abrasion\u002Ferosion).\n* Confirmed recurrent bacterial vaginosis and candidiasis.\n* Patient able to maintain a patient diary during the study.\n* Patient is able to read and understand the language and content of the study materials, understands the requirements for follow-up visits, is willing to provide information at scheduled assessments, and is willing and able to comply with study requirements.\n\nExclusion Criteria:\n\n* Patients who do not sign the informed consent form\n* Other gynecological diseases, immunosuppressive diseases (e.g., HIV infection), or who are immunocompromised for reasons such as corticosteroid therapy, chemotherapy, anti-angiogenic agents, or immunosuppressants, patients with diabetes\n* Patients receiving antibiotics, anti-inflammatory agents, analgesics, antineoplastic drugs, or immunosuppressants within 4 weeks prior to study inclusion\n* History of connective tissue diseases, e.g., systemic lupus erythematosus, systemic sclerosis, Sjogren's syndrome, or mixed connective tissue disease\n* Known allergy to any component of the device\n* Subjects unable to understand the informed consent form or who have a high likelihood of non-compliance with study procedures and\u002For non-completion of the study according to the investigator's judgment\n* Pregnancy and breastfeeding\n* Time between the last day of the last menstrual period and the baseline visit \\>16 days or ≤5 days (for non-menopausal subjects).\n* Participation in other clinical studies","FEMALE","18 Years",{"count":55,"type":20},34,"12 Days","OBSERVATIONAL","The medical device It is indicated to promote the re-epithelialization processes of the vaginal mucosa, in the prevention of vaginal conditions of bacterial and fungal origin, and as an adjuvant in their treatment.\n\nThe primary efficacy endpoint is based on the VAS symptom score (abnormal vaginal discharge, lower abdominal pain, dysuria, burning micturition, dyspareunia, vulvar irritation, and itching on a 10-point scale), specifically the percentage of patients with therapeutic success, defined as resolution of signs and symptoms of recurrent bacterial and fungal infections (total symptom score \\\u003C2) at the end of treatment.",[60,61],"Bacterial Infections","Treatment of Fungal Infections, Candidiasis",[63,64,65,66,67],"candidiasis","bacterial infection","RepHegyn","pH restoring","barrier action","NOT_YET_RECRUITING",{"date":70,"type":36},"2026-04-14",{"date":72,"type":20},"2026-05",{"date":74,"type":20},"2026-08",{"name":42,"class":43},{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":4,"eligibilityCriteria":82,"healthyVolunteers":83,"sex":52,"minAge":16,"maxAge":84,"enrollmentInfo":85,"targetDuration":4,"studyType":21,"phases":87,"briefSummary":88,"conditions":89,"keywords":92,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":96,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":5},"100618404","evaluation-of-performance-and-safety-of-innea-and-innea-aqua-for-the-treatment-of-cheek-and-dcolletage-wrinkles-100618404","NCT07331181","Evaluation of Performance and Safety of INNEA and INNEA AQUA for the Treatment of Cheek and décolletage Wrinkles","A Post-Market, Single-arm, Confirmatory Interventional Clinical Investigation to Evaluate the Performance and Safety of INNEA and INNEA AQUA for the Treatment of Cheek and décolletage Wrinkles","Inclusion Criteria:\n\n1. Patient Informed consent form (ICF) signed;\n2. Female Subjects between 35 and 65 years old at the time of the signature of ICF;\n3. Subjects with at least 2 (shallow wrinkles) on the Lemperle Rating Scale requiring correction of cheek wrinkles and\u002For subjects requiring correction of décolletage wrinkles;\n4. Willingness to follow all study procedures, including attending all site visits, tests and examinations;\n5. Agreeing to present at each study visit without make-up;\n6. Willingness not to undergo other procedures involving aesthetic correction (e.g., ultrasound-based treatments, biomaterial implant, lifting, botulinum toxin injections, laser or intense pulsed light treatment, bio-stimulating treatment, chemical peeling, dermabrasion, fillers) during the entire study period;\n7. Willingness to follow indications to not be exposed to make-up for 12 hours after injection;\n8. Willingness to avoid prolonged exposure to sunlight and UV or using saunas or Turkish baths for one week after the injection.\n\nExclusion Criteria:\n\n* Other - different - clinical conditions of the skin (i.e. rosacea,psoriasis, vitiligo, active eczema, severe scleroderma, severe acne and diagnosticated cancer with\u002Fwithout ongoing antitumor therapy); 2. Infectious or inflammatory processes near the area of intervention; 3. Presence of naevi in the area to be injected; 4. Ongoing use or exposure to benzalkonium chloride solutions; 5. Patients who tend to develop hypertrophic scarring; 6. Patients with a history of autoimmune disease or who are receiving immune therapy; 7. Patients who are known to be hypersensitive to hyaluronic acid; 8. Presence of cutaneous disease on the tested area, as lesions, malformations and recurrent facial\u002Flabial herpes; 9. Presence of tendon, bone or muscular implants near the areaof intervention; 10. Ongoing cutaneous allergies; 11. Known hypersensitivity to cheloids; 12. Allergy or contraindications to device components; 13. Allergy or contraindication to one of the components of local anesthetic (patch or cream); 14. Immune system illnesses; 15. Diabetes mellitus or uncontrolled systemic diseases (endocrine, hepatic renal, cardiac, pulmonary, neurological disorder); 16. Problems with coagulation or undergoing anticoagulant therapy; 17. Patients who are using substances that can prolong bleeding(such as aspirin, nonsteroidal anti-inflammatory drugs, and warfarin); 18. Current treatment with anti-inflammatory drugs, anti-histaminic, topic and systemic corticosteroids, narcotic, antidepressant, immunosuppressive drugs (with the except of contraceptive or hormonal treatment starting more than 1 year ago), drugs able to influence the test results in the investigator opinion; 19. Known drug and\u002For alcohol abuse; 20. Mental incapacity that precludes adequate understanding or cooperation; 21. Any previous permanent and nonpermanent cutaneous treatment for aesthetic correction (e.g., ultrasound-based treatments, biomaterial implant, lifting, botulinum toxin injections, laser or intense pulsed light treatment, bio-stimulating treatment, chemical peeling, dermabrasion, fillers) within 6 months prior to study inclusion; 22. Active malignant neoplasm of any type, or history of a malignancy (patients with a history of other malignancies that have been surgically removed and who have no evidence of recurrence for at least five years before study enrollment are also acceptable); 23. Pregnancy or breastfeeding; 24. COVID-19 vaccination within one month prior to study inclusion; 25. Current participation in a similar study or during the previous 3 months.",true,"65 Years",{"count":86,"type":20},55,[23],"A Post-Market, Single-arm, Confirmatory Interventional Clinical Investigation to evaluate the Performance and Safety of INNEA and INNEA AQUA for the treatment of cheek and décolletage wrinkles",[90,91],"Wrinkle","Aging",[93,94,95],"wrinkles","aging of the skin","Innea-2022",{"date":97,"type":36},"2026-04-16",{"date":99,"type":36},"2023-06-01",{"date":101,"type":20},"2026-12-30",{"name":42,"class":43},""]